Va ricordato che si tratta di dati a 72 settimane su surrogate endpoints istologici: la parte 2 del trial valuter limpatto sulla progressione clinica verso la cirrosi
*Corresponding Author: Rehan Haider, Riggs Pharmaceuticals, Department of Pharmacy University of Karachi Pakistan
USA 110 , 1867418679 (2013)
Evolution and challenges of new obesity drugs related to adverse effects and future direction Combatting obesity represents a major health dilemma, as it contributes to a heightened risk of disease, diminishes the quality of life, and can reduce life expectancy
The fact that most of the studies included only live-born infants and did not record or observe stillbirths, spontaneous abortions, or induced abortions due to severe malformations, potentially led to underestimations of the strength of the associations between SSRIs and fetal congenital malformations
Involve family members or carers if appropriate